Left ventricular reverse remodelling after aortic valve replacement in severe valvular aortic stenosis - effect of blockade of the angiotensin-II receptor

Trial Profile

Left ventricular reverse remodelling after aortic valve replacement in severe valvular aortic stenosis - effect of blockade of the angiotensin-II receptor

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2013

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Aortic valve stenosis; Atrial fibrillation
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Sep 2010 Results published in the American Journal of Cardiology.
    • 01 Sep 2010 Status changed from active, no longer recruiting to completed, based on an article published in the American Journal of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top